Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 9/20 | 0.41 |
| ▸ | NPY1R | P25929 | 5/20 | 0.41 |
| ▸ | NPY2R | P49146 | 4/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | KCNB1 | Q14721 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10262675 | 0.93 | NPY4R (0.42) | NPY4RNPY1RNPY2RNPY5RAAK1 | |
| SCHEMBL15277771 | 0.93 | NPY4R (0.42) | NPY4RNPY1RNPY2RNPY5RAAK1 | |
| SCHEMBL12444369 | 0.93 | NPY4R (0.42) | NPY4RNPY1RNPY2RNPY5RAAK1 | |
| SCHEMBL16285905 | 0.93 | NPY4R (0.42) | NPY4RNPY1RNPY2RNPY5RAAK1 | |
| SCHEMBL15138938 | 0.93 | NPY4R (0.42) | NPY4RNPY1RNPY2RNPY5RAAK1 | |
| SCHEMBL10261740 | 0.93 | NPY4R (0.44) | NPY4RNPY1RNPY2RNPY5RAAK1 | |
| SCHEMBL15277754 | 0.91 | NPY4R (0.43) | NPY4RNPY1RNPY2RNPY5RAAK1 | |
| SCHEMBL19945118 | 0.91 | NPY4R (0.43) | NPY4RNPY1RNPY2RNPY5RAAK1 | |
| SCHEMBL13973694 | 0.91 | NPY4R (0.41) | NPY4RNPY1RNPY2RNPY5RAAK1 | |
| SCHEMBL12514984 | 0.91 | NPY4R (0.41) | NPY4RNPY1RNPY2RNPY5RAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802683-B2 | Compounds for use in treatment of mucositis | CELLCEUTIX CORPORATION (US) | 2014-08-12 | — | — | US | disclosed |
| US-20120295922-A1 | Compounds For Use In Treatment Of Mucositis | POLYMEDIX, INC. (US) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295922-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | NPY4R 4770/4885NPY1R 4756/4885NPY2R 4442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.